Introduction to the Discussion of Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes.

Technology plays a pivotal role in enhancing precision medicine within cancer care.

In the fifth article of this series, Yazan Madanat, MD, reviews recent updates presented at the 2023 ASH Annual Meeting and discusses the evolving treatment landscape.

In this companion article, Dr Peter Voorhees provides insights into effective management of patients with newly diagnosed multiple myeloma (NDMM).

In this companion article, Dr Tanios Bekaii-Saab provides insights into effective management of patients with metastatic colorectal cancer.

Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.